3Kohne CH,Van Cutsem E,Wils JA, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986[J]. Proc Am Soc Clin Oncol, 2003,22 : 1018.
二级参考文献9
1[1]Saltz LD, Cox JV, Blanke C, et al. Irinotecan plus flurouracial and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 2000, 343:905
2[2]Douillard JY, Cuningham D, Roth AD, et al. A randomized phase Ⅲ trial comparing irinotecan (IRI) + 5-FU/FA in patients with metastatic colorectal cancer as first-line chemotherapy.Proc ASCO, 1995, 18, 233 (Abstr, 899),
3[4]Migguel M,, Salud A, Garcia C, et al. Irinotecan (CPT-11)in advanced colorectal cancer patients with progression after therapywithS-FU. Annals of Oncol, 2000, 11 (Supple4) :56
4[5]Zufia L, Castellanos C, Aldaz A, et al. Severe neutropenia in irinotecan (CPT-11 ) treated colorectal cancer patients is related to the exposure to the drug. Proc Am, 2003, 22:163
5[7]Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI follow by FOLFOX versus FOLFOX follow by in metastatic colorectal cancer: Final results of phase Ⅲ study (Abstr). Proc ASCO[c]. J ClinOncol, 2001, 20:1249
7[9]Bouzid K, Khalfallah S, Jujakouski J, et al. A randomized phase Ⅱ trial of irinotecan in combination with infinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol, 2003, 14 (7) :1106
